Please Wait
Applying Filters...
menu
    • menu
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Menu

    Galcanezumab

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Exclusive: US FDA finds new manufacturing lapses at Eli Lilly plant
    Exclusive: US FDA finds new manufacturing lapses at Eli Lilly plant

    20 Jan 2024

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-finds-new-manufacturing-lapses-eli-lilly-plant-2024-01-19/

    REUTERS
    20 Jan 2024
    Share Share
    Teva drops migraine-drug patent case against Eli Lilly
    Teva drops migraine-drug patent case against Eli Lilly

    25 Nov 2023

    // REUTERS

    https://www.reuters.com/legal/litigation/teva-drops-migraine-drug-patent-case-against-eli-lilly-2023-11-24/#:~:text=The%20filing%20follows%20a%20judge\\\'s,dismissed%20on%20Wednesday%20in%202021

    REUTERS
    25 Nov 2023
    Share Share
    Eli Lilly's migraine drug fails to prove superiority to Pfizer's
    Eli Lilly's migraine drug fails to prove superiority to Pfizer's

    17 Jun 2023

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/eli-lillys-migraine-drug-fails-meet-main-goal-post-approval-study-2023-06-16/

    REUTERS
    17 Jun 2023
    Share Share
    First-Of-Its-Kind Head-to-Head Clinical Trial Reaffirms the Efficacy of Emgality
    First-Of-Its-Kind Head-to-Head Clinical Trial Reaffirms the Efficacy of Emgality

    16 Jun 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/first-of-its-kind-head-to-head-clinical-trial-reaffirms-the-efficacy-of-emgality-in-episodic-migraine-prevention-301852663.html

    PR NEWSWIRE
    16 Jun 2023
    Share Share
    AffaMed Therapeutics to commercialize Galcanezumab for Migraine Prevention
    AffaMed Therapeutics to commercialize Galcanezumab for Migraine Prevention

    17 Jan 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/affamed-therapeutics-to-commercialize-galcanezumab-for-migraine-prevention-in-mainland-china-301720180.html

    PR NEWSWIRE
    17 Jan 2023
    Share Share
    Eli Lilly hit by migraine drug launch slowdown, but rivals jump
    Eli Lilly hit by migraine drug launch slowdown, but rivals jump

    06 Aug 2022

    // Ben Adams FIERCEPHARMA

    https://www.fiercepharma.com/marketing/eli-lilly-hit-migraine-drug-launch-slowdown-and-reyvow-no-show-rivals-biohaven-abbvie

    Ben Adams FIERCEPHARMA
    06 Aug 2022
    Share Share